These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18080504)

  • 1. [Encouraging results of stem cell transplantation following a melphalan-preceding intensified preparative regimen for refractory acute leukemia in children].
    Inoue M; Yasui M; Sawada A; Koyama M; Kondo O; Miyamura T; Higuchi B; Kouroki M; Ishihara T; Kawa K
    Rinsho Ketsueki; 2007 Nov; 48(11):1470-7. PubMed ID: 18080504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
    Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
    Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
    O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M
    Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
    Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
    Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia].
    Matsuyama T; Kato K; Hanada R; Kawa K; Okamura J; Tsuchida M; Kigasawa H; Watanabe A; Hamamoto K; Kudoh T; Sano K; Ohira M;
    Rinsho Ketsueki; 2002 Jul; 43(7):527-37. PubMed ID: 12229121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
    Qazilbash MH; Saliba RM; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Flosser T; Couriel DR; De Lima M; Kebriaei P; Popat U; Alousi AM; Champlin RE; Giralt SA
    Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
    Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
    Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma.
    Drabko K; Zawitkowska-Klaczynska J; Wojcik B; Choma M; Zaucha-Prazmo A; Kowalczyk J; Gorczynska E; Toporski J; Kałwak K; Turkiewicz D; Chybicka A
    Pediatr Transplant; 2005 Oct; 9(5):618-21. PubMed ID: 16176419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma.
    Vassal G; Tranchand B; Valteau-Couanet D; Mahé C; Couanet D; Schoeppfer C; Grill J; Kalifa C; Hill C; Ardiet C; Hartmann O
    Bone Marrow Transplant; 2001 Mar; 27(5):471-7. PubMed ID: 11313680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent high-dose melphalan followed by auto-SCT for relapsed and refractory Hodgkin lymphoma in children and adolescents.
    Guilcher GM; Rizzuti FA; Lewis VA; Stewart DA
    Bone Marrow Transplant; 2012 Mar; 47(3):395-8. PubMed ID: 21552303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.
    Beaven AW; Moore DT; Sharf A; Serody JS; Shea TC; Gabriel DA
    Cancer Invest; 2011 Mar; 29(3):214-9. PubMed ID: 21314330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
    Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
    Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second allogeneic peripheral blood stem cell transplants with reduced-intensity conditioning.
    Ruiz-Argüelles GJ; Gomez-Almaguer D; Tarin-Arzaga LD; Morales-Toquero A; Cantu-Rodriguez OG; Manzano C
    Rev Invest Clin; 2006; 58(1):34-8. PubMed ID: 16789597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies.
    Busca A; Bruno B; Boccadoro M; Locatelli F; Falda M
    Med Sci Monit; 2002 Oct; 8(10):RA221-32. PubMed ID: 12388932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.